Literature DB >> 17087858

Advanced glycation end products and vascular structure and function.

Georgia Soldatos1, Mark Emmanuel Cooper.   

Abstract

Diabetes mellitus has now reached epidemic proportions in the Western world. The associated microvascular and macrovascular complications are a result of severe metabolic derangement, which leads to chronic tissue injury. Although there are a number of proposed pathophysiologic mechanisms for the vascular complications associated with diabetes, this review focuses predominantly on the role of advanced glycation end products (AGEs) in the pathogenesis of diabetes-associated atherosclerosis. The potential role of AGEs in enhancing arterial stiffness, an entity occurring with a greater prevalence in populations known to have higher-than-normal AGE levels, is also examined. Pharmacologic interventions aimed at reducing the level of these chemical compounds or interrupting their action provide hope for the future treatment of both atherosclerotic vascular disease and systolic hypertension, particularly in the setting of diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17087858     DOI: 10.1007/s11906-006-0025-8

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  52 in total

Review 1.  Lipid and lipoprotein modification by advanced glycosylation end-products: role in atherosclerosis.

Authors:  R Bucala
Journal:  Exp Physiol       Date:  1997-03       Impact factor: 2.969

2.  Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia.

Authors:  E Leibovitz; N Hazanov; R Zimlichman; M Shargorodsky; D Gavish
Journal:  Am J Hypertens       Date:  2001-11       Impact factor: 2.689

3.  Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Authors:  Colomba Falcone; Enzo Emanuele; Angela D'Angelo; Maria P Buzzi; Chiara Belvito; Mariaclara Cuccia; Diego Geroldi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia.

Authors:  R Marfella; K Esposito; R Giunta; G Coppola; L De Angelis; B Farzati; G Paolisso; D Giugliano
Journal:  Circulation       Date:  2000-05-16       Impact factor: 29.690

6.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

7.  Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.

Authors:  T Niwa; T Katsuzaki; S Miyazaki; T Miyazaki; Y Ishizaki; F Hayase; N Tatemichi; Y Takei
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

Review 8.  Advanced protein glycosylation in diabetes and aging.

Authors:  M Brownlee
Journal:  Annu Rev Med       Date:  1995       Impact factor: 13.739

9.  The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.

Authors:  Francesco Cipollone; Annalisa Iezzi; Maria Fazia; Mirco Zucchelli; Barbara Pini; Chiara Cuccurullo; Domenico De Cesare; Giovanni De Blasis; Raffaella Muraro; Roberto Bei; Francesco Chiarelli; Ann Marie Schmidt; Franco Cuccurullo; Andrea Mezzetti
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

10.  Preferential stiffening of central over peripheral arteries in type 2 diabetes.

Authors:  Eiji Kimoto; Tetsuo Shoji; Kayo Shinohara; Masaaki Inaba; Yasuhisa Okuno; Takami Miki; Hidenori Koyama; Masanori Emoto; Yoshiki Nishizawa
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

View more
  10 in total

1.  Glycolaldehyde induces synergistic effects on vascular inflammation in TNF-α-stimulated vascular smooth muscle cells.

Authors:  Hee-Weon Lee; Min Ji Gu; Guijae Yoo; In-Wook Choi; Sang-Hoon Lee; Yoonsook Kim; Sang Keun Ha
Journal:  PLoS One       Date:  2022-07-05       Impact factor: 3.752

Review 2.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

3.  Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications.

Authors:  Anjuman Gul; M Ataur Rahman; Asmat Salim; Shabana U Simjee
Journal:  Age (Dordr)       Date:  2008-09-03

4.  Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.

Authors:  Brian P Shapiro; Theophilus E Owan; Selma F Mohammed; Donna M Meyer; Lisa D Mills; Casper G Schalkwijk; Margaret M Redfield
Journal:  Circulation       Date:  2008-08-18       Impact factor: 29.690

Review 5.  [Update on diabetic macroangiopathy].

Authors:  J Kunz
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

6.  Reduced Venous Compliance in Young Women with Type 1 Diabetes - Further Aggravated by Prolonged Elevated Levels of HbA1c.

Authors:  Marcus Lindenberger
Journal:  Front Endocrinol (Lausanne)       Date:  2016-09-21       Impact factor: 5.555

Review 7.  Molecular Mechanisms Responsible for Increased Vulnerability of the Ageing Oocyte to Oxidative Damage.

Authors:  Bettina P Mihalas; Kate A Redgrove; Eileen A McLaughlin; Brett Nixon
Journal:  Oxid Med Cell Longev       Date:  2017-10-18       Impact factor: 6.543

8.  Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension.

Authors:  Bogna Gryszczyńska; Magdalena Budzyń; Beata Begier-Krasińska; Angelika Osińska; Maciej Boruczkowski; Mariusz Kaczmarek; Alicja Bukowska; Maria Iskra; Magdalena Paulina Kasprzak
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

9.  Central pulse pressure and its hemodynamic determinants in middle-aged adults with impaired fasting glucose and diabetes: the Asklepios study.

Authors:  Julio A Chirinos; Patrick Segers; Thierry C Gillebert; Marc L De Buyzere; Caroline M Van Daele; Zubair A Khan; Umair Khawar; Dirk De Bacquer; Ernst R Rietzschel
Journal:  Diabetes Care       Date:  2013-04-22       Impact factor: 19.112

10.  Decreased circulatory response to hypovolemic stress in young women with type 1 diabetes.

Authors:  Marcus Lindenberger; Torbjörn Lindström; Toste Länne
Journal:  Diabetes Care       Date:  2013-10-15       Impact factor: 19.112

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.